United Services Automobile Association Takes Position in IQVIA Holdings Inc. $IQV

Key Points

• United Services Automobile Association acquired 4,054 shares of IQVIA Holdings Inc. in the first quarter, valued at approximately $719,000.
• IQVIA reported a quarterly EPS of $2.81, exceeding analysts' estimates, with revenue reaching $4.02 billion, a 5.3% increase year-over-year.
• Multiple investment firms raised their target prices for IQVIA, with UBS Group increasing it from $185.00 to $225.00 and giving a "buy" rating, highlighting strong analyst interest in the stock.

United Services Automobile Association acquired a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 4,054 shares of the medical research company's stock, valued at approximately $719,000.

A number of other hedge funds have also made changes to their positions in IQV. Pacer Advisors Inc. increased its holdings in shares of IQVIA by 5,036.1% during the 1st quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company's stock valued at $153,681,000 after acquiring an additional 854,732 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of IQVIA by 45.7% during the 1st quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company's stock valued at $448,686,000 after acquiring an additional 798,534 shares during the last quarter. Hawk Ridge Capital Management LP acquired a new position in shares of IQVIA during the 1st quarter valued at about $77,096,000. Nuveen LLC acquired a new position in shares of IQVIA during the 1st quarter valued at about $76,328,000. Finally, GAMMA Investing LLC increased its holdings in shares of IQVIA by 27,448.4% during the 1st quarter. GAMMA Investing LLC now owns 387,331 shares of the medical research company's stock valued at $68,286,000 after acquiring an additional 385,925 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on IQV. JPMorgan Chase & Co. decreased their target price on IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research note on Monday, May 19th. Barclays raised their price objective on IQVIA from $165.00 to $185.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 23rd. Jefferies Financial Group upgraded IQVIA from a "hold" rating to a "buy" rating and boosted their price objective for the company from $195.00 to $225.00 in a research report on Tuesday. Citigroup restated a "neutral" rating on shares of IQVIA in a research report on Thursday, May 22nd. Finally, Redburn Partners set a $214.00 price objective on IQVIA in a research report on Wednesday, September 3rd. Eighteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $229.64.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares in the company, valued at approximately $557,352.30. The trade was a 15.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the sale, the insider directly owned 27,178 shares of the company's stock, valued at $5,165,178.90. This trade represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.60% of the company's stock.

IQVIA Price Performance

Shares of IQVIA stock traded down $3.35 during midday trading on Friday, hitting $187.34. 946,284 shares of the company were exchanged, compared to its average volume of 1,144,220. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The firm has a market cap of $31.85 billion, a P/E ratio of 27.11, a PEG ratio of 2.09 and a beta of 1.32. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $248.03. The firm has a 50 day simple moving average of $182.40 and a 200-day simple moving average of $167.42.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. During the same quarter last year, the company earned $2.64 EPS. IQVIA's revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.